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Abstract
Background: Type 2 diabetes is a serious clinical problem in both India and the UK. Adoption of a healthy lifestyle
through dietary and physical activity modification can help prevent type 2 diabetes. However, implementing
lifestyle modification programmes to high risk groups is expensive and alternative cheaper methods are needed.
We are using a short messaging service (SMS) programme in our study as a tool to provide healthy lifestyle advice
and an aid to motivation. The aim of the study is to assess the efficacy and user acceptability of text messaging
employed in this way for people with pre-diabetes (HbA1c 6.0% to ≤6.4%; 42–47 mmol/mol) in the UK and India.
Methods/design: This is a randomised, controlled trial with participants followed up for 2 years. After being
screened and receiving a structured education programme for prediabetes, participants are randomised to a control
or intervention group. In the intervention group, text messages are delivered 2–3 times weekly and contain
educational, motivational and supportive content on diet, physical activity, lifestyle and smoking. The control group
undergoes monitoring only. In India, the trial involves 5 visits after screening (0, 6, 12, 18 and 24 months). In the UK
there are 4 visits after screening (0, 6, 12 and 24 months). Questionnaires (EQ-5D, RPAQ, Transtheoretical Model of
Behavioural Change, and food frequency (UK)/24 h dietary recall (India)) and physical activity monitors (Actigraph
GT3X+ accelerometers) are assessed at baseline and all follow-up visits. The SMS acceptability questionnaires are
evaluated in all follow-up visits. The primary outcome is progression to type 2 diabetes as defined by an HbA1c of
6.5% or over(India) and by any WHO criterion(UK). Secondary outcomes are the changes in body weight, body
mass index, waist circumference, blood pressure, fasting plasma glucose; lipids; proportion of participants achieving
HbA1c ≤6.0%; HOMA-IR; HOMA-β; acceptability of SMS; dietary parameters; physical activity and quality of life.
Discussion: The study is designed to assess the efficacy of tailored text messaging in addition to standard lifestyle
advice to reduce the progression from prediabetes to type 2 diabetes in the two different countries.
Trial registration: ClinicalTrials.gov; NCT01570946, 4th April 2012 (India); NCT01795833, 21st February 2013 (UK).
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Background
The burden of type 2 diabetes in both India and the UK
is high and predicted to rise. In India, the prevalence in
adults is 7.3%, although figures vary from state to state
and in urban versus rural settings [1–3]. In England,
6.7% of the population aged over 17 years are known to
have diabetes [4]. A large proportion of both populations
have intermediate levels of hyperglycaemia, or so-called
pre-diabetes, and this constitutes an identifiable sub-
group who are at high risk of progression to diabetes
[5–7] and in whom preventive interventions have been
shown to be effective [8–12].
A major challenge in applying high risk individual-
level diabetes prevention strategies to large sub-groups
within the population is that the successful lifestyle
modification interventions employed in clinical trials are
labour intensive and expensive and thus difficult to oper-
ationalise at scale. Our intervention strategy attempts to
overcome this issue of scalability by employing a lifestyle
modification programme delivered by short messaging
service (SMS) in both India and the UK. Text messa-
ging is cheap and feasible and has been successfully
used to modify behaviour in other contexts such as
smoking cessation [13, 14].
The primary outcome is progression to diabetes. Sec-
ondary outcomes include cardiovascular disease (CVD)
risk factors, dietary intake, physical activity, and quality
of life (EQ-5D).
Methods/design
This is a randomised, controlled trial with participants
followed up for 2 years.
In India, pre-screening occurs in the workplace (In-
dian railways and other employers) and is performed by
dedicated trained research staff [15]. Men and women
are selected for subsequent screening if, on a question-
naire and a short anthropometric assessment, they have
3 or more of the following diabetes risk factors: age 35
to 55 years; family history of diabetes; personal history
of hypertension; sedentary life-style; previous gestational
diabetes; known prediabetes; waist circumference ≥
90 cm in males, ≥80 cm in females; body mass index
(BMI) ≥ 23 kg/m2. Screening is based on haemoglobin
A1c (HbA1c) levels, measured using a point-of-care
device using capillary blood. People are invited to join
the trial if they have HbA1c levels in the upper prediabe-
tes range (HbA1c 6.0% to ≤6.4%, 42 to 47 mmol/mol)
[16–18]. Pre-screening and screening are typically per-
formed on the same day. People who are discovered to
have diabetes are referred for routine care by their
physicians.
In the UK, pre-screening identifies people as having
prediabetes of any degree (by national and international
criteria for either glucose or HbA1c) [19] in the National
Health Service (NHS) Health Check programme, or in
other in-house health screening programmes in primary
care. The NHS Health Check is offered to men and
women aged 40 to 74 years. In-house programmes may
be offered to people of 18 years or over. Following con-
sent, participants have their HbA1c measured and are
considered eligible for the trial if the result is in the
upper prediabetes range [17, 18] (as in India). If HbA1c
is measured in the pre-screening stage, and if this is
within 1 week of full screening, then this value is ac-
cepted for inclusion in the trial. Anyone whose HbA1c is
in the diabetic range is referred for routine care for their
diabetes. The study has been adopted by the National
Institute for Health Research Clinical Research Network
(NIHR CRN) and trained CRN staff perform much of
the recruitment and subsequent activity. Recruitment
flowchart in India and the UK is shown in Fig. 1.
In India, the trial involves 5 visits after screening (0, 6,
12, 18 and 24 months). In the UK there are 4 visits after
screening (0, 6, 12 and 24 months).
Screening visit
In India, participants have their height, weight, waist
circumference, blood pressure and heart rate measured.
A point of care device (Bio-Rad, boronate affinity chro-
matography) is used for HbA1c testing. Random glucose
(Accu-Check, Roche Diagnostics) is also measured for
all participants.
In the UK, participants attend fasting and their height,
weight, waist circumference, hip circumference, blood
pressure and heart rate are measured. Venous blood
(15 ml) is taken for measurement of HbA1c, glucose and
fasting lipids. A serum sample is stored for biomarker
measurement. A random urine sample is taken for meas-
urement of the albumin: creatinine ratio.
In both countries, questionnaires are completed
(EQ-5D, RPAQ, Transtheoretical Model of Behavioural
Change (TTM), and food frequency/24 h dietary recall).
People are classified by TTM stage. Physical activity
monitors (Actigraph GT3X+ triaxial accelerometers) are
fitted and participants are asked to wear them on the
lower back for 7 days and nights. Pre-paid addressed
envelopes are provided for the return of monitors.
Education and randomization visit
In India, participants attend fasting. Venous blood
(15 ml) is taken for measurement of fasting glucose and
lipids. A serum sample is stored for biomarker measure-
ment. In both India and the UK, a structured education
programme for prediabetes is delivered including: defin-
ition; implications for progression to diabetes; preven-
tion of type 2 diabetes; healthy lifestyle advice including
dietary and physical activity advice, supplemented by
written materials.
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Participants are then randomised to a control (standard
care) or intervention (standard care plus SMS) group.
Follow-up visits
These are the 6, 12, 18 and 24 month follow-up visits.
Participants are fasting for all visits in the UK, and only
for the 12- and 24-month visits in India. The 18-month
visit is omitted in the UK. The assessments and mea-
surements are as per baseline;
TTM staging is decided and SMS content modified
on this basis. The acceptability of receiving the text
messages is assessed by questionnaire at each follow-
up visit.
The questionnaires employed in the project have been
validated or used previously in similar settings. The
EQ-5D-3 L in India (the EQ-5D-5 L in the UK) is a vali-
dated quality of life questionnaire which measures the
effects of disease and health status on perceived quality
of life [20, 21]. It describes 5 health related quality of life
dimensions (mobility, self-care, usual activities, pain/dis-
comfort, and anxiety/depression) all of which can take
one of 3 or 5 responses depending on the level of sever-
ity. The Recent Physical Activity Questionnaire (RPAQ)
provides a validated estimate of physical activity, enab-
ling physical activity energy expenditure (PAEE) and
time spent in different intensity levels to be calculated
[22, 23]. Physical activity is classified as home activities,
activity at work, recreation, and transport. The Food
Frequency Questionnaire (FFQ), employed in the UK
sample, is a validated questionnaire for calculation of
intake of dietary energy and of the major food constitu-
ents [24–27]; it has also been compared to 24-h dietary
recall [28–30]. The 24-h dietary recall, employed in
India, has been used previously by the Indian investiga-
tors in this setting [14]. It enumerates the food ingested
from morning until bedtime and records dietary habits,
food choices, food frequency and quality. The SMS
acceptability questionnaire was developed for our feasi-
bility study of SMS in diabetes prevention [14]. It as-
sesses acceptability of text contents and message
frequency. The TTM questionnaire is described below in
the section on interventions. Clinical assessments and
other activities at each visit are shown in Fig. 2.
Primary outcome
In both countries, the primary outcome is progression
to diabetes.
In India, progression to diabetes is defined at any
follow-up visit by HbA1c ≥ 6.5% (48 mmol/mol) [16, 19].
In the UK, progression to diabetes is defined by any
national and international criterion (Fasting plasma glu-
cose (FPG) or HbA1c) at any visit, or in another care
setting. The criteria for diagnosis of diabetes [16, 19, 31]
are:
1. Symptoms and FPG ≥7.0 mmol/l or HbA1c ≥ 6.5%.
2. No symptoms but one of the following;
Fig. 1 Recruitment flowchart in India and the UK
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 FPG ≥7.0 mmol/l and HbA1c ≥ 6.5%; tests are
repeated after 4 weeks and FPG ≥7.0 mmol/l
and/or HbA1c ≥ 6.5%.
 FPG < 7.0 mmol/l and HbA1c ≥ 6.5%; repeat
HbA1c after 4 weeks and if the second result is
≥6.5%
 FPG ≥7.0 mmol/l and HbA1c < 6.5%; repeat FPG
after 4 weeks and if the second result is
≥7.0 mmol/l.
The reason for the difference in definitions is the
different clinical settings in the two countries. In India,
with the trial conducted in and around the workplace by
dedicated trial staff, HbA1c was the single measure of
glycaemia employed. In the UK, with recruitment in
primary care and continued primary care involvement
over the 2 years thereafter, other plasma glucose based
criteria were also accepted as these were often the mea-
sures employed by the primary care staff.
Fig. 2 Clinical assessments and other activities at each visit
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Secondary outcomes
 The proportion of participants achieving HbA1c ≤
6.0%.
 FPG.
 Weight, BMI, waist circumference.
 Systolic and diastolic blood pressure.
 Total cholesterol, HDL cholesterol, LDL cholesterol,
triglycerides.
 HOMA-IR, HOMA-β.
 Intakes of total energy, fat and carbohydrates.
 PAEE from self-report: total, home, work, commut-
ing, leisure activity and total physical activity, time
spent in moderate vigorous physical activity, time
spent sedentary, total movement volume and inten-
sity distribution (from accelerometry).
 Summary measure of quality of life from EQ-5D.
 Acceptability of SMS as a communication medium.
Design/randomisation
Participants are randomised to the control or interven-
tion group. In the intervention group, text messages are
delivered 2–3 times weekly and contain educational,
motivational and supportive content on diet, physical
activity, and smoking. The message content varies de-
pending on the participant’s TTM stage.
Lifestyle modification targets are in line with previ-
ously published diabetes prevention studies [32]:
1. Minimum 150 min moderate intensity exercise per
week
2. A minimum of 7% weight loss or achieving a BMI
of 25 kg/m2 (23 kg/m2 in India)
3. < 30% of total dietary energy intake from fat
4. < 10% of total dietary energy intake from saturated
fat
5. > 15 g fibre per 1000 kcal dietary intake
Data are stored in a secure, non-identifiable manner
for later statistical analysis.
Randomization to the intervention or control group
is performed in India using a computer-generated
randomization sequence, Matlab randperm version 6
based on Marsaglia’s algorithm [33]. In the UK, ran-
domisation is provided by a commercial organisation
(sealedenvelope.com) and performed in random per-
muted blocks with stratification by sex [male, female],
age [< 35, 35–50, 50–65, > 65 years] and body mass
index [< 28, 28–32, > 32 kg/m2].
Setting
In India, pre-screening based on risk factors is per-
formed in the workplace, having obtained prior per-
mission from employers. Employees provide informed
consent to undergo pre-screening, screening and trial
entry and may withdraw at any time. In the UK,
pre-screening occurs in primary care using the NHS
Health Checks or other in-house schemes. If eligible,
informed consent is obtained. Trial visits take place
in CRN sites in NHS premises close to participants’
homes.
Ethics, informed consent, and safety
The study is conducted in accordance with the recom-
mendations for physicians involved in research on hu-
man subjects adopted by the 18th World Medical
Assembly, Helsinki 1964 and later revisions.
Written consent is obtained from each participant
after full explanation, an information leaflet offered and
time allowed for consideration. The right of the partici-
pant to refuse to participate, or continue participating,
without giving reasons and without prejudicing further
treatment is respected. The Chief Investigator in each
country ensures that participant confidentiality is respected
and local data protection requirements are met.
In India, ethical approval is in place from an inde-
pendent Institutional Review Board. In the UK, approval
is from the Westminster Research Ethics Committee
and Site Specific Assessment (SSA) plus R&D approvals
were in place at each participating NHS Trust. Imperial
College Academic Health Science Centre acts as the
main Sponsor. Delegated responsibilities are assigned to
the NHS trusts taking part in this study. Only research staff
trained in Good Clinical Practice participate in the project
to obtain informed consent and conduct procedures.
The study is subject to inspection and audit by the
sponsors, ensuring adherence to Good Clinical Practice
and other aspects of research governance.
Eligibility – Inclusion criteria
HbA1c was chosen as the measure on which to define
eligibility; it has the advantage over measuring circulat-
ing free glucose that it requires only random blood
samples as opposed to fasting samples or samples timed
in relation to ingestion of oral glucose. It reflects average
circulating glucose levels over the preceding 4–8 weeks
and has similar biological significance (in terms of the
complications of diabetes) to that of free glucose
measurements. Following standardisation by the Inter-
national Federation of Clinical Chemistry, it is recog-
nised internationally as a diagnostic test for diabetes
with a cut-off at ≥6.5% [31]. For prediabetes, although
the American Diabetes Association has recommended
the HbA1c range of 5.7–6.4% [31], international consen-
sus has not been reached on this. We are using 6.0–6.4%
for recruitment in both India and the UK to include only
patients at very high risk. In the UK, men and women
with prediabetes aged 18 to 74 years and HbA1c levels
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in this range are recruited. The age range in India is 35
to 55 years.
Eligibility – Exclusion criteria
Subjects are excluded if
HbA1c values render the participant eligible (HbA1c
6.0% to ≤6.4%) but FPG is in the WHO diagnostic range
for diabetes (≥7.0 mmol/l) – a necessary requirement as
people in the UK were assessed by any WHO criterion;
pregnant or planning pregnancy; breastfeeding; enrolled
in other clinical trials; active malignancy or under inves-
tigation for malignancy; unable to follow the protocol
(Version 9, 17/03/2015) for any reason. FPG above the
WHO diagnostic range was considered an exclusion
criterion as it is a primary outcome in the UK.
Estimated timeline
Participants are followed up for 2 years.
Interventions
Usual care is given to both the groups and consists of a
one-to-one interview, delivering personalised diet and
exercise advice, supplemented by standard written ma-
terial and education regarding prediabetes and diabetes.
Usual care is delivered once at the beginning of the
study.
Participants in the intervention arm receive tailored
text messages based on healthy lifestyle principles. Mes-
sages are sent 2–3 times a week and tailored to the par-
ticipants’ TTM stage.
A database of SMS text messages had been developed
based on previous work [14], modified and expanded for
use in both India and the UK. In addition, for the UK
site, a Patient and Public Involvement Group in the
CRN provided input into the SMS message design and
content. The messages provide tips, suggestions, and
positive reinforcement or encouragement for healthy
behaviours. Content includes goal setting and self-moni-
toring, understanding intensity of physical activity, diet-
ary energy and portion control, personal strategies for
lifestyle change and overcoming barriers. Routine phys-
ical activity, time management, meal planning, and strat-
egies for eating out also feature. To keep the text
messaging novel and non-repetitive, the type and con-
tent of the messages change from day to day, and at-
tempts are made to minimise message repetition.
Message content is modified depending on TTM
stage. TTM is a behavioural theory which is widely
applied in health research interventions aiming to
induce behavioural change [34]. It is derived from key
theories in psychotherapy. The four core constructs of
the model are the “stages of change,” “processes of
change,” “decisional balance,” and “self-efficacy”. The
processes of change relate to ‘how’ individuals change
their behaviour. They include cognitive, affective, evalu-
ative and behavioural strategies that an individual may
adopt to modify behaviour. The TTM is implemented in
this study to assess an individual’s status in terms of
behavioural change and to attempt to improve it. Indi-
viduals’ TTM stage is assessed at the start of the study
and followed during the 2 year period.
Safety assessments
The trial is conducted in compliance with Good Clinical
Practice principles with which all investigators are con-
firmed to be familiar and the applicable regulatory
requirement(s).
The study is subject to inspection and audit by Imper-
ial College London under their remit as sponsor and
other regulatory bodies to ensure adherence to Good
Clinical Practice in Research and the NHS Research
Governance Framework for Health and Social Care.
Data
Data is locally collected and transferred to the central
database. The data is coded and anonymised and then




Diabetes prevention trials that employ intensive lifestyle
intervention and monitoring have achieved reductions in
progression to diabetes in those at risk of between 36
and 65%. Based on earlier data from the Indian Diabetes
Prevention studies, a 2 year conversion rate to diabetes
of 25% could be expected in people with prediabetes in
the absence of intervention. We have reported a 36%
reduction in 2-year risk in a trial of SMS for diabetes
prevention in 537 men in India [14]. In order to detect
reductions in risk of 20% and 30% with 80% power at 5%
significance, and allowing for 4% dropout, we estimated
that recruitment totals of 2268 and 976 respectively,
would be required. We therefore chose 20% as a nom-
inal expectation for the minimum risk reduction, requir-
ing a sample of 2268 participants, 1134 in each of the
two groups to be compared.
Data reduction
The raw 50 Hz triaxial accelerometry data were con-
verted into vector magnitude (VM) activity counts in 5-s
epochs. We classified the intensity distribution in fine-
grained bins, and also collapsed into broader intensity
categories of sedentary time (< 200 counts per min),
light (200–2500 cpm), moderate-to-vigorous PA (>
2500 cpm); the latter level discriminates between slow
walking and higher intensity locomotion [30]. Non-wear
time was defined as prolonged (> 90 min) periods of
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inactivity; this was taken into account using a cosine
method [35] when summarising total volume (average
intensity) and time spent in different intensity categories
for each participant and visit. Individual records with
less than 72 h of wear time and less than 8 h wear in
each time quadrant of the day were excluded from
analysis.
Analysis plan
Analyses will be performed using Stata version 14.2 [36]
and R [37] and will follow the recommendations of the
CONSORT 2010 statement (www.consort-statement.org).
The primary efficacy outcome will be development of
Type 2 diabetes, defined as HbA1c ≥ 6.5% in India, and
any WHO criterion in the UK.
A hazard ratio comparing the intervention vs control
group for Type 2 diabetes, together with a 95% confi-
dence interval and p-value will be estimated using a
discrete-time proportional hazards model [38], which
takes into account the fact that the data are interval
censored, i.e. HbA1c is measured at protocol-defined
visits [6,12,(18), 24 months], so in individuals who
develop diabetes (HbA1c ≥ 6.5%), the exact time that it
developed is not known. Individuals who withdraw from
the study or who have not developed Type 2 diabetes by
the end of follow-up will be censored at their last avail-
able follow-up time.
For each of the continuous secondary efficacy outcomes
measured at multiple time points during follow-up, the
mean and standard deviation of the values at each time
point will be calculated. Differences between the interven-
tion and control groups at each time point and 95% CI
will be estimated from a linear regression model with
random intercepts at the individual level (to allow for
repeated measures), including the baseline value of the
outcome and parameters for randomized group, time and
randomized group-by-time interaction. For the objectively
measured physical activity outcomes, accelerometer wear
time will also be included in the model. Outcome vari-
ables with a skewed distribution (Triglyceride, HOMA-IR,
HOMA-β) will be summarized using the median and
Interquartile Range and log transformed before being ana-
lysed using the model described above.
All outcomes will be analysed including all individuals
in the group to which they were randomized, regardless
of whether the intervention was actually received (based
on the Intention-to-Treat principle). The primary effi-
cacy outcome will also be analysed using a Per Protocol
population, which reclassifies individuals in whom the
intervention was not deemed to have been successfully
delivered because text messages had been blocked on
the mobile phone during the first 6 months of follow-up.
The analyses described above will be performed separ-
ately on data from India and the UK, and also on a
combined dataset, where models will be adjusted for
country. For the primary efficacy outcome, the inter-
action between randomised group and (1) country, (2)
sex will be tested by including the relevant multiplicative
interaction parameter in the model. Estimated hazard
ratios for type 2 diabetes and 95% confidence intervals
will be reported separately in men and women.
Publication policy
The study results will be disseminated by peer reviewed
scientific journals, internal report, conference presenta-
tion and publication on websites. No identifiable per-
sonal data will be published. All anthropometry and
personal clinical data will be expressed as mean/ median
and spread of the population in the study. All partici-
pants will be informed of the results at the conclusion of
the study and details of any publications that arise from
the study will be disseminated to participants.
Sponsor
The sponsor for the study is Joint Research Compliance
Office, Imperial College London and Imperial College
Healthcare NHS Trust.
Discussion
The study aims to discover whether progression from
prediabetes to type 2 diabetes can be reduced with tai-
lored text messaging (in addition to standard lifestyle
advice) in two different environments (India and the
UK). If the result is positive, text messaging could
provide an inexpensive adjunct to diabetes prevention
programmes globally.
The clinical settings in India and the UK are very
different, necessitating different recruitment strategies in
the two countries (workplace in India and primary care
in the UK), criteria for pre-screening and criteria for
diagnosis (although in both countries the criteria are
compatible with national and international recommen-
dations [17, 18]). In India the study is conducted with
employers’ consent close to the workplace by dedicated
staff whereas in the UK, NIHR CRN staff performed
most of the studies as part of their wider clinical
research remit. As a result, and for pragmatic reasons
the UK site omits the 18-month visit. The text message
content is also slightly modified in each country to
ensure compatibility with the dietary and physical activ-
ity behaviours in the two settings. Within one country,
the same intervention and assessment methodologies are
applied to all participants.
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